a-Glucosidase (AGH) from the small intestine of rat was immobilized onto a glutaradehyde (GA) activated NH2-96 well microplate to establish a convenient and rapid AGH inhibition assay system. After AGH immobilization, remaining GA groups were blocked by b-alanine to induce a negative charge on the surface of the well. The AGH-plate showed an enzyme activity of 444 nU/well under an assayed condition at 37˚C for 2 h using 0.3 mM 4-methylumbelliferyl-a-Dglucopyranoside as a fluorogenic substrate. Inhibitory powers of voglibose and acarbose as therapeutic AGH inhibitors were successfully evaluated to have IC50 values of 13 and 114 nM, respectively.
Introduction
Recent studies regarding the prevention or improvement of noninsulin-dependent diabetes mellitus (NIDDM) provide useful information that the long-term intake of a-glucosidase (AGH, exo-type a-D-glucoside O-linkage hydrolase, EC 3.2.1.20) inhibitor, acarbose, to achieve moderate blood glucose level (BGL) was effective for improving hyperglycemia in borderline NIDDM subjects. 1 This indicates that achieving a high BGL close to as normal as possible through the retardation of AGH activity or inhibition of the digestive process of carbohydrates in the gut could be useful for treating diabetic patients. In this respect, we have clarified natural AGH inhibitors, including acylated anthocyanins, 2, 3 caffeoylquinic acids 4 and theaflavins 5 as an alternative medicinal food compound.
Along with screening studies of natural AGH inhibitors, we have also proposed a new immobilized AGH (iAGH) assay system to mimic the membrane-bound condition 6 since AGH in mammalian intestine is anchored in the membrane by the polypeptide chain spanning the bilayer only once in the manner of N(in)/C(out) orientation 7 to form a sucrase-isomaltase (SI) complex. 8 The use of the iAGH assay system allowed the prediction of an in vivo antihyperglycemic effect of a given compound with iAGH inhibitory activity; compounds with less iAGH inhibitory activity were no longer candidates responsible for postprandial BGL lowering, even if they showed apparent AGH inhibitory activity by a conventional free AGH assay. 9, 10 However, the proposed iAGH assay still provided great effort, because it requires each set of a reaction column containing AGH-immobilized support for each assay sample. In this study we, thus, undertook to develop a convenient iAGH-microplate assay capable of successive evaluation of the AGH inhibitory activity in one run-in assay.
Experimental

Materials
Rat intestinal acetone powder was purchased from Sigma Chemical Co. (St. Louis, MO). Papain (14 U/mg-solid, from papaya latex, EC. 3.4.22.2) was a product of Nacalai Tesque (Kyoto, Japan). 4-Nitrophenyl-a-D-glucopyranoside (pNPG) and 4-methylumbelliferyl-a-D-glucopyranoside (MUG) were products of Sigma Chemical.
Voglibose 
Preparation of immobilized AGH-aminoplate
A 96 well-aminoplate was subjected to a glutaradehyde (GA) activation treatment. The surface of each well was activated with 150 ml of 2.5% GA coupling buffer (0.2 M phosphate buffer, pH 8.0) for 2 h at 20˚C. After being rinsed with deionized water and 50 mM phosphate buffer (pH 8.0), 150 ml of purified AGH (0.1 mg/ml) in the coupling buffer was added to the GA-activated well. The purification of AGH from rat intestinal acetone power was done according to our previous report. 6 After incubation at 20˚C for 2 h, the well was washed with 50 mM phosphate buffer (pH 8.0) containing 0.5 M NaCl, followed by the addition of 150 ml of a 0.1 M blocking reagent. In this experiment, four reagents (b-alanine, 2-aminoethanol, n-propylamine and ethylenediamine) were used to block any remaining active aldehyde groups to introduce carboxyl (COOH), hydroxyl (OH), methyl (CH3) or amino (NH2) group onto the well, respectively. After blocking at 20˚C for 2 h, the support was throughly rinsed with 50 mM phosphate buffer (pH buffer. Immobilization of AGH (0.1 mg/ml) onto carboxylplate was performed by direct condensation with 75 ml of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) (40 mg/ml) in 20 mM phosphate buffer (pH 6.0) at 4˚C for 24 h.
Inhibition assay for immobilized AGH
The immobilized AGH activity was assayed as follows. The iAGH-plate was directly suspended in 200 ml of a substrate solution (50 mM phosphate buffer, pH 7.4). pNPG (0.7 mM) or MUG (0.3 mM) was used as a synthetic AGH substrate for measuring the overall iAGH activity. After incubation at 37˚C for 2 h, the activity was determined by measuring the change in the fluorescent intensity on a Wallac 1420 Multilabel counter (Perkin Elmer Co., Tokyo, Japan). Excitation and emission wavelengths were set at 390 and 410 nm for pNP detection or at 355 and 460 nm for MU detection, respectively. During a kinetic study, the substrate concentration was set at 0.1 -1.0 mM for measuring Km and Vmax from the Lineweaver-Burk plots. One unit of iAGH activity was defined as the amount of enzyme to hydrolyze 1 mmol of substrate per min per well under the above-assayed conditions.
For an iAGH inhibition study, to the well of iAGH-microplate, 20 ml of an inhibitor solution and 180 ml of a substrate solution were added directly. After incubation at 37˚C for 2 h, the iAGH inhibitory activity was determined by the difference in the iAGH activity with or without an inhibitor. The concentration of the AGH inhibitor required to inhibit 50% of the AGH activity under the assayed condition was defined as the IC50 value.
Stability test of prepared iAGH-microplate
The stability of the prepared iAGH-microplate activity was assessed as a function of the storage times of 1, 4, 7, 21 and 37 days after preparation. The well or iAGH-microplate was immersed in 50 mM phosphate buffer (pH 6.8) at 4˚C until the assay.
Animal experiment
Male 7-wk-old Sprague-Dawley rats (SPF/VAF Crj: SD, Charles River Japan, Kanagawa) were fed a laboratory diet (CE-2, Clea Japan, Tokyo) and given water ad libitum. All rats were housed for 1 week at 21 ± 1˚C and 55 ± 5% humidity under controlled lighting from 8:30 to 20:30.
Single oral administration of voglibose (dose; 0.07, 0.34, 0.76 mg kg -1 ) or acarbose (dose; 1.5, 2.0, 3.0 mg/kg) was conducted in SD rats withheld for 16 h by gavage. After 5 min, 2 g/kg of a substrate (maltose) solution was administered to each rat. Control rats were administered with the same substrate solution without an inhibitor. At each time point to 120 min, about 20 ml of blood sample was collected from the tail vein, being immediately subjected to a BGL measurement by a disposable glucose sensor (Glutest Pro, Sanwa Chemical Research, Co., Tokyo, Japan). The ED50 value, which is the effective dose required to achieve 50% suppression of BGL rise, was interpolatively estimated. 
Results and Discussion
Assessment of iAGH-microplate assay
Considering that the possible immobilization amount of AGH would be extremely low towards the surface area of well (<1 cm 2 ), MUG with high fluorescent intensity at a level of pmol was used as a substrate throughout the study. Though data were not shown, the fluorogenic detection range of pNPG, a common substrate for carbohydrases, was as narrow as 0.2 -1 mmol/assay volume.
On the basis of our previous finding 6 on preferential introduction of negative charges onto AGH-support by b-alanine to mimic the intestinal epithelium microvilli containing glycocalyx, such as sialic acid and uronic acid, 11 iAGHmicroplate blocked by b-alanine was primarily used for optimizing the incubation time. As shown in Fig. 1 , the production of 4-methylumbelliferon (MU) from MUG by iAGH action was linear with the incubation time to 4 h for both carboxylplate and aminoplate.
Considering the apparent difference in the fluorescent intensity between the blank and the sample (>100000) and rapid incubation, we set at an incubation time of 2 h for both plates' assay in this study. The activities of iAGH-aminoplate and iAGH-carboxylplate were estimated to be 444 and 585 nU/well, respectively.
Catalytic property of iAGH-microplates
The effect of the blocking reagent on the iAGH activity was investigated. As summarized in Table 1 , the kinetics of the prepared plates greatly differed from induced groups onto aminoplate; b-alanine and 2-aminoethanol-induced aminoplates showed similar Km values as carboxylplate, whereas plates blocked by ethylenediamine and n-propylamine provoked less affinity with MUG. The difference in the kinetics for each prepared plate may be due to the accessibility of MUG to a charged plate. Among the prepared plates, b-alanine-aminoplate did show a high catalytic efficiency (vmax/Km) of 0.08 as well as carboxylplate. This indicates that the introduction of carboxyl groups onto the surface of the plate was more favorable for the activation of immobilized AGH, being matched with an anionic environment of the intestinal epithelium microvilli by acid mucopolysaccharides. Table 2 summarizes the inhibition of acarbose and voglibose against iAGH-microplates with different blocking groups. Apparently, the prepared plates showed a variety of inhibitory activities with blocking groups. b-Alanine-and n-propylamineinduced plates showed potent IC50 values of around 20 nM for voglibose, while no, or poor, inhibitory activity was observed in the other treated plates including carboxylplate. A similar inhibitory behavior in the plates was observed for acarbose. These results strongly suggested that the surface polarity of the plate induced by various blocking reagents greatly affected the inhibitory action of both inhibitors against AGH as well as the kinetic behavior (Table 1) .
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Inhibition studies of iAGH-microplates
In the present SD rat experiments to evaluate in vivo antihyperglycemic potency of therapeutic AGH drugs (voglibose and acarbose), the intake of voglibose to 8wk-SD rats showed an ED50 of 0.55 mg/kg in maltose-loaded rats, whereas a 5.6-times higher dose of acarbose was required for lowering the BGL rise (ED50; 3.1 mg/kg) (Fig. 2) . Odaka et al. 12 also reported a higher antihyperglycemic potency of voglibose, rather than acarbose by a factor of 14.6 times in sucrose (2.5 g/kg)-loaded SD rat (ED50: acarbose, 5.42 mmol/kg; voglibose, 0.37 mmol/kg). These findings indicate that the magnitude of the in vivo antihyperglycemic power of voglibose would be potentially >5-fold stronger than that of acarbose. From the viewpoint of the antihyperglycemic potency of both inhibitors, we re-examined the IC50 values of both inhibitors assayed by iAGH-plates ( Table 2) . As a result, the ratio of the IC50 value of voglibose to acarbose greatly differed from induced blocking groups onto the plates; a comparable ratio of 8.5 with in vivo antihyperglycemic ED50 value was observed for the b-alanineiAGH plate. A lower ratio of the IC50 value (0.4) by the carboxylplate than the b-alanine-iAGH plate suggested the importance of a spacer from the b-alanine skeleton to mimic the in vivo inhibition of intestinal membrane-bound AGH. The reproducibility of the iAGH activity for the b-alanine-iAGH plate was 4.5% of the correlation of the coefficient (n = 8).
Stability of iAGH activity of the b-alanine-induced microplate
The change in the iAGH activity of b-alanine-aminoplate stored at 4˚C was examined up to 37 days after preparation. As shown in Fig. 3 , the prepared plate retained its AGH activity of >60% during 21 days after preparation, while the activity disappeared at 37 days. This revealed that a reliable evaluation for AGH inhibition would be possible within 3 week-storage after preparation of the iAGH-plate, although attempts to improve the stability of the AGH activity of the plate are needed.
Achieving BGL close to normal as possible has been considered to be one of the major goals of NIDDM therapy, in which the inhibition of intestinal AGH could be useful for improving an excess postprandial BGL rise from dietary carbohydrates. In this study, we established an iAGH-b-alanineaminoplate to evaluate the inhibition of intestinal membrane- bound AGH. The assay would overwhelm a conventional free AGH assay system, because of its possible estimation of an in vivo suppression effect of BGL rise by any inhibitors. The established assay was also preferable to our previous iAGHSephadex support assay, 6 because of simultaneous determinations for evaluating AGH inhibition of many targeted samples in onerun-in assay.
